Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2002 3
2003 2
2004 2
2005 2
2006 4
2007 7
2008 7
2009 3
2010 7
2011 5
2012 4
2013 2
2015 1
2016 3
2017 2
2018 3
2019 2
2020 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project. Rosenwald A, et al. Among authors: hurt em. N Engl J Med. 2002 Jun 20;346(25):1937-47. doi: 10.1056/NEJMoa012914. N Engl J Med. 2002. PMID: 12075054 Free article.
Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models.
Agarwal S, Fang L, McGowen K, Yin J, Bowman J, Ku AT, Alilin AN, Corey E, Roudier MP, True LD, Dumpit R, Coleman I, Lee JK, Nelson PS, Capaldo BJ, Mariani A, Hoover C, Senatorov IS, Beshiri M, Sowalsky AG, Hurt EM, Kelly K. Agarwal S, et al. Among authors: hurt em. J Clin Invest. 2023 Nov 15;133(22):e162148. doi: 10.1172/JCI162148. J Clin Invest. 2023. PMID: 37725435 Free PMC article.
Targeting prostate cancer stem cells.
Crea F, Mathews LA, Farrar WL, Hurt EM. Crea F, et al. Among authors: hurt em. Anticancer Agents Med Chem. 2009 Dec;9(10):1105-13. doi: 10.2174/187152009789735053. Anticancer Agents Med Chem. 2009. PMID: 19925394 Review.
Cancer stem cell plasticity and tumor hierarchy.
Cabrera MC, Hollingsworth RE, Hurt EM. Cabrera MC, et al. Among authors: hurt em. World J Stem Cells. 2015 Jan 26;7(1):27-36. doi: 10.4252/wjsc.v7.i1.27. World J Stem Cells. 2015. PMID: 25621103 Free PMC article. Review.
Signatures of the immune response.
Shaffer AL, Rosenwald A, Hurt EM, Giltnane JM, Lam LT, Pickeral OK, Staudt LM. Shaffer AL, et al. Among authors: hurt em. Immunity. 2001 Sep;15(3):375-85. doi: 10.1016/s1074-7613(01)00194-7. Immunity. 2001. PMID: 11567628 Free article. Review.
Targeting cancer stem cells with phytochemicals.
Kawasaki BT, Hurt EM, Mistree T, Farrar WL. Kawasaki BT, et al. Among authors: hurt em. Mol Interv. 2008 Aug;8(4):174-84. doi: 10.1124/mi.8.4.9. Mol Interv. 2008. PMID: 18829843 Review.
The role of IL-6 and STAT3 in inflammation and cancer.
Hodge DR, Hurt EM, Farrar WL. Hodge DR, et al. Among authors: hurt em. Eur J Cancer. 2005 Nov;41(16):2502-12. doi: 10.1016/j.ejca.2005.08.016. Epub 2005 Sep 30. Eur J Cancer. 2005. PMID: 16199153 Review.
55 results